Skip to main content
Industry News
Aminoglycoside antibiotics show promise in frontotemporal dementia

Researchers found that the aminoglycoside antibiotics G418 and gentamicin enabled nerve cells with a genetic mutation that prevents progranulin protein production, which is evident in people with frontotemporal dementia, to recover up to 50% to 60% of progranulin levels. The study in Human Molecular Genetics "provides an important proof of concept that these aminoglycoside antibiotics or their derivatives can be a therapeutic avenue for frontotemporal dementia," said researcher Haining Zhu.

Full Story: